Report #2868133

Received Oct 24, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 41 yrs
State: VA
Recovered: Unknown
Vaccinated: Oct 1, 2025
Onset: Oct 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	UNK	2293B	IM

Symptoms (1)

Product administered to patient of inappropriate age

Symptom narrative

administration of Arexvy in a patient under 50 years of age; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 41-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 2293B, expiry date 05-DEC-2026) for prophylaxis. On 01-OCT-2025, the patient received Arexvy (intramuscular). On 01-OCT-2025, an unknown time after receiving Arexvy, the patient experienced inappropriate age at vaccine administration (Verbatim: administration of Arexvy in a patient under 50 years of age). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK Receipt Date: 07-OCT-2025 A pharmacist enquired about the availability of clinical data regarding the administration of Arexvy in patients below 50 years of age. The pharmacist mentioned that the vaccine was given in a facility.